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Fetal growth restriction (FGR) remains a leading contributor to perinatal mortality and morbidity and metabolic syndrome in
later life. Recent advances in ultrasound and Doppler have elucidated several mechanisms in the evolution of the disease. However,
consistent classification and characterization regarding the severity of FGR is lacking. There is no cure, and management is reliant
on a structured antenatal surveillance program with timely intervention. Hitherto, the time to deliver is an enigma. In this paper,
the challenges in the diagnosis and management of FGR are discussed. The biophysical profile, Doppler, biochemical and molecular
technologies that may refine management are reviewed. Finally, a model pathway for the clinical management of pregnancies
complicated by FGR is presented.

1. Introduction
Fetal growth restriction (FGR) refers to a fetus that has failed
to achieve its genetically determined growth potential and
aﬀects up to 5–10% of pregnancies. Fetal growth restriction is associated with an increase in perinatal mortality
and morbidity. This is because of a high incidence of
intrauterine fetal demise, intrapartum fetal morbidity, and
operative deliveries. In preterm FGR, which occurs before 34
weeks gestation, iatrogenic prematurity is a pertinent issue.
Neonates aﬀected by FGR suﬀer from respiratory diﬃculties,
polycythemia, hypoglycemia, intraventricular hemorrhage,
and hypothermia [1–3]. In the long-term cerebral palsy,
developmental delay and behavioral dysfunction can occur.
Increasing evidence points to a link between FGR and
adult metabolic syndrome [4, 5]. Barker et al. found, in
a longitudinal study of 13 517 men and women born
between 1924 and 1944 in Helsinki University Hospital that
a combination of small size at birth, followed by accelerated
weight gain during childhood, seemed to be responsible for
an increased risk of coronary heart disease, type 2 diabetes,
and hypertension. It is postulated that FGR may direct a fetal
compensatory mechanism that alters adult susceptibility to
disease [4, 5].

The occurrence of a fetus that is small for gestational
age (SGA) and thus smaller than its expected size is
well recognized. The diagnostic challenge is in distinguishing SGA pregnancies from FGR pregnancies because the
majority of SGA pregnancies are associated with a good
prognosis compared to FGR pregnancies [6]. The World
Health Organization defines SGA as a neonatal weight of
less than 2500 grams at term [7], a definition that eliminates
the impact of accurate pregnancy dating and allows its use
in developing countries. The use of an estimated weight
below the 10th percentile for gestational age or weight that
is less than two SD below the anticipated value for the
gestational age [8] is more widely adopted in developed
countries. In some cases, SGA is defined as weight below
the 5th or even 3rd percentile. Fetuses with a birthweight
below the 10th percentile may not be growth restricted but
rather constitutionally small. The lower the percentile cutoﬀ, the greater the recognition of FGR [9]. Whilst workable,
these definitions risk failing to detect fetuses that have fallen
across percentile lines from their original trajectories but
remain above the 10th percentile. Growth decline and rate
of decline in late pregnancy are important considerations
[10]. Marconi et al. recently evaluated the outcome of FGR
infants with abnormal pulsatility index of the umbilical
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artery according to the neonatal birth weight/gestational
age standards and intrauterine growth charts. They found
that 47% of FGR pregnancies had a birthweight above
the 10th percentile (FGR/appropriate for gestational age)
compared to 53% with birthweight below the 10th percentile
(FGR/SGA). The neonatal morbidity and mortality were
similar in FGR of the same clinical severity, whether or
not they could be defined as appropriate or small for
gestational age according to the neonatal growth standards
[11]. Therefore, relying on growth charts and standards, or
simple percentile cut-oﬀs, may be insuﬃcient for diagnosing
FGR. Mathematical models by Deter et al. and customized
growth charts by Gardosi have been shown to improve the
detection of growth restriction [12–14]. Deter defined the
Prenatal Growth Assessment Score (PGAS) and Neonatal
Growth Assessment Score (NGAS) as measures for detecting
growth abnormalities. The NGAS allows identification of
neonates that had growth problems in utero and reflects
an overall assessment of growth outcome. Evaluation of
neonatal growth abnormality is important because of the
potential postnatal neurological and behavioralal consequences of pathological pregnancies. Deter’s model’s have
proved useful in detecting FGR in multifetal pregnancies
[13, 15, 16]. Gardosi’s customized charts adjust for maternal
factors with the benefit of reducing adverse outcome. There
is some evidence that correcting for maternal characteristics
alone may not be suﬃcient to improve detection of FGR
[17, 18]. Developments in Doppler of the maternal and fetal
circulation, fetal heart rate analysis, and biophysical profile
have improved the diagnosis of both FGR and SGA. SGA
pregnancies often exhibit normal fetal Doppler [19], whilst
FGR due to placental disease exhibits characteristic maternal
and fetal Doppler abnormalities. This paper discusses the
challenges in the diagnosis and management of FGR.

2. Etiology and Pathophysiology
2.1. Causes. It is important to identify etiological factors
in FGR because this directs the managing physician to
an early diagnosis. The causes of FGR are fetal, maternal,
environmental, and placental (Table 1). Fetal causes are less
common and include aneuploidy (trisomies 13, 18, and
21), fetal malformations, and congenital infections (rubella,
cytomegalovirus, rubella, toxoplasmosis) [20]. Multifetal
gestations have a high incidence of FGR. About 20–30% of
dichorionic twin pregnancies will suﬀer from FGR, as will
40% of monochorionic twin pregnancies. This is due to
placental sharing which places a stress on the uteroplacental
circulation. Maternal conditions such as pre-eclampsia and
pre-existing or gestational hypertension are leading causes
of maternal mortality and morbidity, and are complicated
by FGR in 30 to 40% of cases [21]. Diabetes is complicated
by FGR in 10 to 20% of cases irrespective of glycemic
control [22]. Maternal vascular disease and thrombophilia
can lead to uteroplacental hypoperfusion thereby impairing
fetal growth [23]. Hypoxia secondary to cardiac, respiratory
and hematological disorders may cause FGR. Similarly,
tobacco and toxic drugs will compromise the intrauterine
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Table 1: Causes of fetal growth restriction.
Fetal
Aneuploidy (trisomy 13, 18 and 21, triploidy, uniparental
disomy)
Fetal malformations (gastroschisis, omphalocele)
Multiple gestation
Infection (toxoplasmosis, rubella, cytomegalovirus, herpes)
Maternal
Hypertension
Diabetes
Renal disease
Vascular disease
Inflammatory bowel disease
Hypoxia (pulmonary disease, cardiac disease)
Systemic lupus erythematosus, antiphospholipid syndrome
Thrombophilia (Factor V Leiden heterozygote, Prothrombin
gene G20210A heterozygote, MTHFR heterozygote)
Maternal uterine malformations (myomas, bicornuate, or septate
uterus)
Residing at altitude
Placental
Placenta praevia
Placental tumors
Mosaicism
Environment
Low socioeconomic status
Malnutrition
Smoking
Alcohol
Drugs (cocaine, heroin, methadone, cocaine, therapeutic agents)

environment [24–30]. These disorders destroy the placental
through chronic infarctions and abruptions, villitis, or fetal
thrombotic vasculopathy [24–30]. In over 20% of fetuses
with idiopathic FGR, confined placental mosaicism (the
presence of at least two cell lines with diﬀerent chromosomal
complements) exist in the placenta [31].
2.2. Placental Dysfunction in Fetal Growth Restriction. Normal placental development and functional integrity are
essential for normal fetal growth. There is extensive evidence
demonstrating that placentation is inadequate in pregnancies
complicated by FGR [32, 33]. The trophoblast is a metabolically active tissue, producing hormones, absorbing nutrients
and eliminating unwanted waste. In early normal pregnancy,
the trophoblast invades the maternal spiral arteries with loss
of smooth muscle and elastic lamina from the vessel walls
as far as the inner third of the myometrium, leading to a
5–10-fold dilation at the vessels and establishment of the
uteroplacental circulation. Using dimensions in the literature
derived from three-dimensional reconstructions, Burton and
colleagues modeled the eﬀects of terminal dilation on inflow
of blood into the placental intervillous space at term and
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observed a modest impact of dilation on blood flow. They
found that dilation slows the rate of flow from 2 to 3 m/s
in the nondilated part of an artery of 0.4–0.5 mm diameter
to approximately 10 cm/s at the 2.5 mm diameter mouth,
depending on the exact radius and viscosity. In the absence
of conversion, blood will enter the intervillous space as
a turbulent jet at rates of 1-2 m/s, which could damage
villous architecture, rupturing anchoring villi and creating
echogenic cystic lesions as evidenced by ultrasound [34].
Histological features seen in the placenta of pregnancies
complicated by FGR include damage to branching angiogenesis with long unbranched intermediate and terminal villi,
cytotrophoblast proliferation, trophoblast apoptosis, fibrin
deposition, syncytial knotting and bridging, and enhanced
villous maturation [30, 35].

3. The Diagnosis of FGR
The maternal history allows individual risk factors for
FGR to be ascertained. Socioeconomic concerns present
opportunities for primary prevention. High-risk populations
include women with poor lifestyle choices, low prepregnancy
weight, or weight gain during pregnancy, previous preterm
delivery, and previous pregnancy aﬀected by FGR [20, 36–
38]. Pregnancy counseling allows the likelihood of FGR
recurrence to be discussed [20, 38]. In maternal medical
conditions, recurrence risk is high and disease control is
a priority. Where there has been a previous stillbirth, it is
essential to establish the cause because of the high incidence
of FGR in such cases.
3.1. Clinical Diagnosis of FGR. A prerequisite for a judicious
diagnosis of FGR is accurate dating of the pregnancy. The last
menstrual period, when certain, reliably dates the pregnancy.
Alternatively, dating is performed with sonography [39].
Abnormal fetal growth is detected with the clinical suspicion
of a subnormal uterine size, followed by abdominal palpation
and direct measurement of the symphyseal-fundal distance
[40]. Abdominal palpation has a sensitivity of 30% for
detecting SGA fetuses. The symphysis-fundal distance has a
sensitivity of 27–86% and specificity of 80–93% for detecting
SGA [41]. The use of customized symphysial-fundal distance
charts which take into account anthropometric characteristics and ethnicity reportedly improve detection [42].
3.2. Role of Sonography in the Diagnosis of FGR. Ultrasound is the benchmark for accurate pregnancy dating
and diagnosis of FGR. However, there is room for error
and FGR is undetected in about 30% of routinely scanned
cases and incorrectly detected in 50% of cases [43]. In the
1970s, Robinson and Fleming described pregnancy dating
according to the fetal crown-rump length (CRL). A first
trimester CRL that is within 5 days of the patient’s menstrual
dating will accurately date the pregnancy. Transvaginal
ultrasound can visualize a gestational sac as early as 4.5
weeks. The gestational sac grows at a mean diameter of 1 mm
per day and can be used to correctly determine gestational
age [44, 45]. Some authors have shown that it is possible
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to detect first trimester FGR. In a retrospective review of
4229 pregnancies, Smith and colleagues found that a firsttrimester CRL that was two to six days smaller than expected
was associated with an increased risk of a birth weight below
2500 g (relative risk, 1.8), a birth weight below 2500 g at term
(relative risk, 2.3), a birth weight below the fifth percentile
for gestational age (relative risk, 3.0) and delivery between
24 and 32 weeks of gestation (relative risk, 2.1) [46]. MookKanamori et al. has found that the association between first
trimester FGR (defined as gestational age-adjusted CRL in
the lowest 20% of the population) and low birth weight was
independent of maternal physical characteristics and lifestyle
choices [47]. Furthermore, a significant relationship between
biparietal diameter (BPD) growth rate between the first and
second trimesters and adverse pregnancy outcome has been
reported. Fetuses with growth rates less than 2.5th centile had
an OR of 4.79 (95% CI, 1.43–15.99) for perinatal death and
an OR of 2.64 (95% CI, 1.51–4.62) for birth weight less than
the sonographically estimated mean fetal weight (adjusted
for gestational age) −2 SD [48].
Second trimester pregnancy dating (prior to 20 weeks
gestation) is reliable if the fetal biometry is within 10 days of
the menstrual date [45]. Femur length, head circumference,
BPD, and abdominal circumference are used up to 28 weeks
gestation [49]. Beyond 20 weeks, the BPD may diverge from
the correct gestational age by 12–15 days, extending to 21
days after 30–32 weeks gestation. Because of this discrepancy,
femur length is frequently chosen as a dependable indicator
of gestational age in late pregnancy [50, 51]. Estimated fetal
weight is calculated using polynomial equations combing
BPD, femur length, and the abdominal circumference. The
most common formulas are those reported by Shepard et
al. and Hadlock et al. [52, 53]. Using these formulas, FGR
is typically defined as estimated fetal weight less than the
10th, 5th, or 3rd percentile for the gestational age or below
2 standard deviations of the mean for the gestational age
[54, 55].
Traditionally, standards for birthweight for gestation
have been based on the average of the population. However,
fetal growth is complex especially in the third trimester
of pregnancy. There remains a need for a method that
distinguishes fetuses that have failed to maintain their growth
potential close to delivery and those that are normal or
genetically small. Deter has suggested an individualized fetal
growth evaluation method where each fetus serves as its
own control [16]. This method has eﬀectively identified
growth abnormalities in fetuses and neonates except in
prenatal cases where only a change in soft tissue has occurred.
Individualized growth assessment (IGA) observes changes in
sonographic measures over time points. A model, developed
by Rossavik calculates expected growth trajectories in the
late 2nd trimester and 3rd trimester for an individual fetus
(each fetus being its own control) and then compares
actual and expected third trimester growth by calculation of
Percent Deviation and Growth Potential Realization Index
values. Multiple sets of anatomical parameters (Prenatal
Growth Profile and the Neonatal Growth Profile) are used
in the models. The calculated growth trajectories of head
circumference (HC), abdominal circumference (AC), thigh
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circumference (ThC), femur diaphysis length (FDL), crownheel length, and estimated weight (EWT) are incorporated in
the models [16, 56]. Prenatal Growth Assessment Scores and
Neonatal Growth Assessment Scores (NGASI) are calculated
from Percent Deviation and Growth Potential Realization
Index (GPRI) values for the anatomical parameters, respectively [16, 56]. A modified Neonatal Growth Assessment
Score (mNGAS) allows for individual growth variability in
growth abnormalities, and has been shown to accurately
detect growth restricted neonates [15].
Gardosi has proposed standards according to an individual growth potential calculated for each baby in each pregnancy. Gardosi’s customized standards are based on certain
principles. Firstly, the standards are adjusted or customized
for sex as well as maternal characteristics such as height,
weight, parity, and ethnic origin. The standards exclude
pathological conditions such as diabetes and smoking which
are known to aﬀect birth weight. Prematurity is also excluded
due to its association with FGR. Factoring the multiple
variables produce, the individually “customized” optimal
weight value for each pregnancy (“Term Optimal Weight”
(TOW) at 280 days) [14]. These customized birthweight
standards have been found to be superior to populationbased standards in their associations with adverse outcomes
such as antepartum haemorrhage, pre-eclampsia, abnormal
Doppler, or Caesarean section for fetal distress, low 5-min
Apgar score, need for neonatal resuscitation, neonatal care
unit admission, poor neurological outcome, and perinatal
death [42, 55, 57, 58]. The Royal College of Obstetricians
and Gynaecologists of the United Kingdom have recommended the use of customized ultrasound charts [59].
Whilst there are clear benefits for customized weight centiles
[14], recent literature attributes the observed benefits in
adverse outcomes to the incorporation of intrauterine-based
reference values at preterm ages rather than the adjustment
made for maternal characteristics. Hutcheon and colleagues
hypothesize that methological diﬀerences between the calculation of customized birthweight standards and conventional
birthweight standards could lead to these benefits. Whilst
maternal factors are adjusted for, the reference values in
customized standards at gestational ages other than 280 days
are derived from an intrauterine standard (because they use a
proportionality formula derived from Hadlock’s intrauterine
standard to extrapolate 280-day expected weights back to
younger gestational ages), as opposed to conventional charts,
which are based on birthweights of newborn infants [17,
60]. In a population-based cohort study of 782 303 births,
Hutcheon and colleagues found that relative risks of stillbirth
and early neonatal mortality among SGA births as classified
by the intrauterine standard (noncustomized) were similar
to those among SGA births as classified by the customized
standard and much higher than those among SGA births
as classified by the birthweight standard. The use of the
customized birthweight standard showed no advantage over
noncustomized intrauterine weight standard in predicting
perinatal mortality [18]. Notably, customization for maternal factors did not hinder the identification of high-risk
infants. Further studies are needed to corroborate these
result.
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This further emphasizes the blurred border between
physiological and pathological influences on fetal growth.
Bukowski et al. demonstrated that individualized optimal
fetal growth norms (physiologic factors were used to individually predict optimal growth trajectory and its variation
and growth potential for each fetus) better identify normal
and abnormal outcomes of pregnancy compared to existing
methods. Growth potential norms correctly classified more
pregnancies than population, ultrasound, or customized
norms in complicated pregnancies [61].
Although largely of historical value, two distinct patterns
of FGR have been described by Campbell and Thoms and
are briefly mentioned for completeness [62]. In symmetrical
FGR, all fetal parts have the same degree of growth.
Aneuploidy, congenital infection, and fetal alcohol syndrome
are associated with symmetrical FGR. In asymmetrical FGR,
the head circumference is spared and the abdominal circumference is reduced. This is attributed to the preferential
shunting of blood to vital organs (brain, heart, and adrenal
glands) due to uteroplacental insuﬃciency. The etiology
and manifestation of symmetric and asymmetric FGR
largely overlap limiting the usefulness of this classification
in defining FGR [54]. The ratio of head circumference
to abdominal circumference as means of distinguishing
asymmetrical growth restriction from symmetrical growth
restriction has gained popularity in some fetal medicine
units. However, these definitions have been superseded by
Doppler and fetal heart rate analysis.
A salient feature observed in FGR is the reduction of
amniotic fluid volume. Amniotic fluid volume is estimated
by a simple subjective assessment or calculation of the
amniotic fluid index (AFI) [63]. Normal AFI implies normal
placental perfusion and points to alternative etiologies of
FGR such as infection, where AFI may be normal or
increased. In contrast, low AFI (oligohydramnios, defined
as AFI less than 5 cm or less than the 5th percentile)
with intact membranes is most commonly associated with
uteroplacental insuﬃciency. Ultrasound is the most common method of measuring amniotic fluid. One second
trimester study compared ultrasound to direct measurement
of amniotic fluid by dye dilution techniques, reporting
good correlation between the two methods (r = 0.815; P
less than .001) [64]. Because ultrasound is subjective, there
may be inaccuracies. Another study comparing ultrasound
to dye dilution techniques in the third trimester found
that amniotic fluid index overestimated the actual amniotic
fluid volume by as much as 88.7% at lower volumes, and
underestimated the actual volume by as much as 53.9% at
higher volumes [65]. Reported regression slopes (r values)
for amniotic fluid index and two-diameter amniotic fluid
pocket compared to actual amniotic fluid volume are 0.34
and 0.23, respectively [66]. Clearly, technical competence is
important in the measurement of amniotic fluid index.

4. Screening for Fetal Growth Restriction
4.1. Serum Biochemistry. First trimester combined screening
for aneuploidy has been the focus of extensive research.
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Models incorporate maternal characteristics and serum
biochemical markers with nuchal translucency in order to
predict adverse outcomes. The levels of some biochemical
markers are altered in SGA and FGR pregnancies. A raised
maternal serum alpha-fetoprotein (AFP) is associated with
an increased risk of low birth weight in the absence of
structural abnormality or aneuploidy [67]. Low levels of
maternal serum pregnancy-associated plasma protein A
(PAPP-A) (at the lowest 5th percentile) are associated with an
increased risk of an SGA infant [68, 69]. A recent multicenter
study related levels of first trimester PAPP-A and second
trimester AFP to adverse pregnancy outcome. In that study,
the odds ratio for delivering an SGA infant for women with
a high AFP was 0.9 (95% CI 0.5–1.6) and for women with
a low PAPP-A was 2.8 (95% CI 2.0–4.0). However, when
a low PAPP-A at 10 to 14 weeks gestation and high AFP
between 15 and 21 weeks gestation were combined, the odds
ratio for delivering an SGA infant was 8.5 (95% CI 3.6–
20.0). Thirty-two percent of women with this combination
delivered a low birth weight neonate (less than 2,500 g) [70].
Several other placental markers are the subject of continued
research including human chorionic gonadotrophin (hCG),
ADAM12 (A Disintegrin and Metalloprotease), Placental
protein 13 (PP13), serum soluble Fas (sFas) and placental
growth factor (PlGF), amongst others. However, results show
that detection rates are below levels warranted for large
population screening [71–76].
In pre-eclampsia, combinations of biochemical and
ultrasonographic markers have been shown to improve
the early prediction of preeclampsia. In low-risk populations, combinations including placental protein 13 (PP13),
pregnancy-associated plasma protein A (PAPP-A), a disintegrin and metalloprotease-12 (ADAM12), activin A, or
inhibin A, measured in first or early second trimester
and uterine artery Doppler in second trimester, reveal
sensitivities of 60%–80% and specificities >80%. In high-risk
populations, the combination of PP13 and pulsatility index
in first trimester showed 90% sensitivity and 90% specificity
in a single study limited to severe pre-eclampsia [77]. Large
studies will be needed to evaluate the full potential of
evaluating combining multiple markers and ultrasound in
screening for pre-eclampsia and FGR.
4.2. Uterine Artery Doppler. Since the 1980s, great strides
have been made in the use of uterine artery Doppler in
obstetric practice, particularly in the detection of maternal
perfusion abnormalities in pre-eclampsia and fetal growth
restriction [78–80]. The remodeling of the maternal spiral
arterioles during trophoblastic invasion is thought to be
mirrored by a fall in impedance to uterine blood flow from
the first to the second trimester of pregnancy. This technique
measures the resistance to blood flow in the uterine artery
(resistance index (RI) or pulsatility index (PI)) by isonating
the vessel at its apparent cross over with the external iliac
artery [81, 82]. Because trophoblastic invasion was thought
to be completed by the second trimester, many of the earlier
studies were performed between 20 and 24 weeks gestation.
Some authors now believe that trophoblastic invasion peaks
in the first trimester and argue that this is a more appropriate
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time to screen for FGR and pre-eclampsia [83]. Martin et al.
reported that increased uterine Doppler PI at 11 to 14 weeks
had a sensitivity of 11.7% for detecting birth weight less than
the 10th percentile, and 27.8% for FGR requiring delivery by
32 weeks gestation [84]. Others have reported sensitivities
of 24% and 16% [85, 86]. Despite these low sensitivities,
women with a high uterine artery mean RI (greater or
equal to the 75th percentile) are 5.5 times more likely to
have an FGR pregnancy [86]. In the second trimester, a
multicentre study of about 8000 women, using a PI above
the 95th percentile (1.63) reported higher sensitivities if FGR
was defined by the 5th compared to the 10th percentile
(19% versus 16%) [87]. In FGR requiring delivery prior to
32 or 34 weeks, sensitivities of 56% and 70% have been
reported, respectively [80, 87]. Newer studies have attempted
to add maternal factors and serum biochemistry such as
PAPPA in order to increase detection rates. Unfortunately,
sensitivities remain unremarkable [71, 88]. There are also
technical concerns with reproducibility, especially in the first
trimester. The role of uterine artery Doppler in established
FGR and in the third trimester is limited. Doppler assessment
of the uterine artery is a work in progress and more studies
are warranted to define its role in screening for FGR.
4.3. Antepartum Fetal Monitoring. The primary objective of
antepartum fetal surveillance is to decrease perinatal mortality and morbidity. When FGR is suspected or identified,
monitoring tools aim to detect features of fetal acidosishypoxemia, which could lead to permanent fetal neurological
damage or stillbirth. Nonreassuring tests prompt delivery,
whilst reassuring tests delay delivery and minimize iatrogenic
prematurity especially at thresholds’ of viability. Fetal heart
rate monitoring, biophysical profile scoring, and multivessel
Doppler are commonly used tests.
4.4. Fetal Heart Rate Monitoring. Fetal heart rate analysis
or nonstress test is a widely used tool in monitoring highrisk pregnancies. It aims to determine fetal well-being by
assessing the fetal heart rate baseline, variability, and periodic
changes. A normal reactive test is likely to reflect adequate
oxygenation of the fetal central nervous system. Because
the fetal heart rate monitoring is interpreted using visual
inspection, it is prone to a significant intraobserver and interobserver variation and therefore has a high false positive
rate for abnormality. In premature fetuses, particularly those
with FGR, interpretation is challenging [89]. Furthermore,
in at least 50% of fetuses with a nonreassuring analysis,
the neonate is found not to have evidence of acidosis [90].
Computerized fetal heart rate analysis has been introduced
to reduce inconsistencies in the interpretation [91]. Computerized fetal heart rate analysis refines the interpretation
of parameters and allows determination of short-term and
long-term variation, which are frequently reduced in fetal
academia [92, 93]. The contraction stress test is another
surveillance tool. Whilst largely superseded by fetal heart
rate analysis and multivessel Doppler, it remains useful in
uncovering a dysfunctional placenta. During this test, the
infusion of oxytocin causes uterine contractions, which are
associated with diminished placental perfusion pressure.
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4.5. Biophysical Profile. The fetal biophysical profile (BPP)
is a group of measurements that includes the amniotic
fluid volume, fetal tone, fetal movements, fetal breathing
movements, and fetal heart rate monitoring (NST). When
normal, each parameter receives two points, for a maximum
total of ten points. In the USA, it is the most acceptable
method of noncontinuous fetal well-being assessment [95–
97]. The individual components of the BPP all reflect fetal
well-being. If evaluation of the AFI reveals oligohydramnios,
this calls for further evaluation irrespective of the overall
score. The measurement of amniotic fluid volume serves
as an indirect estimate of fetal urine production, a marker
of fetal renal perfusion. When all other parameters are
within normal limits, the need for an NST is questionable.
Manning et al. described a high-risk pregnancy protocol
where routine NST was not performed when all other BPP
parameters were normal [98]. Others view the NST and
the BPP as independent predictors of normal outcome [99].
The BPP is usually performed to lower the false positive
rate of the NST; however, the BPP has a false positive
rate ranging from 75% for a score of six to 20% for
a score of zero. Vibroacoustic stimulation, a noninvasive
technique that stimulates fetal activity during the BPP test,
has been suggested as a means of reducing the false positive
rate [100]. The main advantages of the BPP test are the
direct assessment of fetal behavior and the technical ease in
performing the test. The disadvantages are the performance
time required (at least 30 minutes), the dependence on
visual interpretation of the NST, and the indirect provision
of information regarding fetal cardiovascular status and
perfusion. Furthermore, randomized trials comparing the
BPP with other tests are lacking [101].
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Fetuses with diminished oxygen reserve will manifest late
deceleration on the fetal heart rate analysis. Freeman et al.
reported that a corrected perinatal death rate was 176.5/1000
for patients with positive CST compared with 2.3/1000 for
patients with a negative test [94].
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4.6. Doppler Velocimetry of Blood Flow. Evaluation of placental and fetal Doppler blood flow has significantly altered the
management of FGR. Doppler is used to determine vascular
resistance and end organ function. Doppler assessment
of the umbilical artery (UA, Figure 1(a)) evaluates blood
flow from the fetus to the placenta and therefore reflects
placental vessel resistance. Doppler assessment of the middle
cerebral artery (MCA, Figure 1(b)) reflects fetal cerebral
blood flow. Doppler interrogation of the ductus venosus (DV,
Figure 1(c)) detects alterations in fetal cardiac function. The
DV is often abnormal in severe cases of FGR [102, 103].
The UA is the most commonly used Doppler surveillance
tool in women diagnosed with FGR. The usefulness of UA
Doppler lies in its ability to distinguish FGR caused by
placental disease from nonhypoxic or constitutional causes
of SGA pregnancies. Early in placental dysfunction, there is
an increase in the resistance to blood flow through the UA,
seen as increased systolic/diastolic (S/D) flow ratio or PI. In
severe placental insuﬃciency, diastolic flow becomes absent

(c)

Figure 1: Doppler velocimetry of fetal vessels. (a) depicts a normal
umbilical artery flow waveform. (b) depicts a normal waveform
of the middle cerebral artery, and (c) depicts an abnormal ductus
venosus waveform, showing a reversed “a” wave.

or reversed, a finding associated with increased perinatal
mortality and morbidity [104–106].
Monitoring FGR pregnancies using UA Doppler has been
shown to reduce mortality rate (OR 0.67, 95% CI, 0.47–
0.97) and lower the need for antepartum admissions, labor
induction, and Caesarean deliveries [106, 107].
The growth restricted fetus reorganizes its blood flow,
shunting blood from visceral, and less essential organs, to
vital organs such as the brain, heart and adrenal glands. This
“brain-sparing” eﬀect is detected by Doppler flow assessment
of the MCA, evidenced as decreased systolic/diastolic ratios
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or PI (Figure 1(b)). In cases of severe fetal hypoxia, there is a
rebound increase in S/D ratio and diminished perfusion even
to the brain. The MCA Doppler does not consistently predict
fetal deterioration [19, 108]. The combination of elevated
MCA PI with UA Doppler may have a role in optimizing
the timing of the delivery of the growth restricted fetus
[107, 109, 110]. Interestingly, MCA peak systolic velocity
(used in the management of fetal anemia) shows promise in
the follow up of fetuses with an established diagnosis of FGR
[111].
The fetal veins that are currently evaluated by Doppler
include the DV, inferior and superior vena cava, and the
umbilical vein. Changes in blood flow in these vessels reflect
the compliance of the fetal heart and its ability to cope
with preload. A decreased or reversed “a” wave of the
DV (Figure 1(c)) is evidence of decreased forward flow in
atrial systole, while pulsations in the umbilical vein reflect
increased central venous pressure [112]. The ductus venosus
is a unique vessel and only a few studies have evaluated
its haemodynamics. Bellotti et al. compared the ductal
ultrasonographic and Doppler findings in two growthrestricted human fetuses with the results of mathematical
simulations of ductal dilatation. They observed apparent
active DV dilatation. Prolonged ultrasonographic analysis
(45 min) showed rapid and substantial changes (>80%) of
ductal diameters suggesting a compensatory eﬀect for which
a higher proportion of the umbilical flow is shunted through
the ductus to the brain and the myocardium [113]. Tchirikov
et al. studied the ability of Doppler ultrasound to evaluate
ductus venosus blood flow during acute hypoxemia in fetal
lambs. Pulsed wave Doppler ultrasound tended to reduce the
mean velocity (V mean) and the minimum velocity (V min)
(based on the maximum velocity envelope curve) in the
DV, descending aorta, and inferior vena cava. The pulsatility
index of the umbilical artery significantly increased at the end
of hypoxemia [114]. Kiserud et al. observed that DV shunting
was higher and the umbilical blood flow to the liver was less
in fetuses with FGR particularly in those with the most severe
umbilical hemodynamic compromise. Fetuses with FGR and
normal UA Doppler did not shunt significantly more than
the reference fetuses but those with raised UA pulsatility
index (>97.5(th) percentile) and those with absent/reversed
end diastolic flow shunted significantly more. With more
DV shunting, these fetuses distributed correspondingly less
umbilical blood to the liver, one of the mechanisms being a
lower perfusion pressure as reflected in the lower DV blood
velocity [115]. In severe FGR, Doppler examination of blood
flow volume revealed a significant increase (>90th percentile
of control fetuses) in the shunting of umbilical vein blood
flow through the DV that was associated with the dilation of
the ductal isthmic diameter [116]. These studies suggest that
the decrease of the a-wave is determined by a dilatation of the
DV.
There have been a number of studies that have evaluated
the sequence of appearance of abnormal Doppler parameters in FGR fetuses with placental dysfunction. Hecker
et al. described the temporal sequence of changes in fetal
monitoring variables in FGR in a prospective longitudinal
observational multicenter study of FGR fetuses after 24
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weeks of gestation. Amniotic fluid index and umbilical artery
pulsatility index were the first variables to become abnormal,
followed by the middle cerebral artery, aorta, short-term
variation, DV, and inferior vena cava. Perinatal mortality was
significantly higher if short-term variation and DV pulsatility
index were abnormal compared to only one or neither
being abnormal. They concluded that DV pulsatility index
and short-term variation of fetal heart rate were important
indicators for the optimal timing of delivery before 32
weeks gestation [117]. Baschat et al. tested the hypothesis
that hemodynamic changes depicted by Doppler preceded
deteriorating biophysical profile score in severe FGR in a
longitudinal study of FGR fetuses in the late second and third
trimester. Forty-four of 236 intrauterine growth-restricted
fetuses (18.6%) required delivery for abnormal biophysical
profile scoring. Three principal patterns of Doppler deterioration were observed: (i) worsening umbilical artery PI,
advent of brain sparing, and venous deterioration (72.7%);
(ii) abnormal precordial venous flows, advent of brain sparing (13.6%), and (iii) abnormal ductus venosus only (9.1%).
In the majority (70.5%), Doppler deterioration was complete
24 h before biophysical profile score decline. In the remainder
(25%), Doppler deterioration and biophysical profile score
<6/10 were simultaneous [102]. Ferrazzi et al. conducted an
observational study in a tertiary care/teaching hospital on
FGR fetuses before 32 weeks’ gestation to compare Doppler
changes as a function of time. Delivery was based on a
nonreactive fetal heart rate tracing and not on Doppler
information. Firstly, for each vessel there was a progressive
increase in the percent of fetuses developing a Doppler
abnormality. Secondly, severely FGR fetuses followed a progressive sequence of acquiring Doppler abnormalities, which
were categorized into “early” and “late” Doppler changes.
Early changes occurred in peripheral vessels (umbilical and
middle cerebral arteries; 50% of patients aﬀected 15-16 days
prior to delivery). Late changes included umbilical artery
reverse flow, and abnormal changes in the DV aortic and
pulmonary outflow tracts (50% of patients aﬀected 4-5 days
prior to delivery). The time interval between the occurrence
of early and late changes was significantly diﬀerent. Late
changes in vascular adaptation by the severely growthrestricted fetus are the best predictor of perinatal death [118].
Presently, it is unclear whether or not there is a
reproducible “sequence” of venous flow alterations in the
growth-restricted fetus to be applied outside of specialist fetal
medicine units. At times, the observed changes in the umbilical vein and ductus venosus temporarily appear to overlap.
Arterial and venous Doppler indices may independently
predict fetal deterioration. In the majority of severely FGR
fetuses, sequential deterioration of arterial and venous flows
precedes terminal changes. Integration of serial Doppler
evaluation of the umbilical artery, middle cerebral artery and
DV to FGR surveillance may improve prediction of outcome
and the timing of intervention [112, 119, 120].
Myocardial performance index is a new parameter that
may be useful in fetal monitoring. A recent study has
explored the sequence of changes of Myocardial Performance Index (MPI), Aortic Isthmus (AoI), and Ductus
Venosus (DV) in fetuses with early-onset FGR. Myocardial
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Performance Index, AoI PI, and DV PI increased with
progressive fetal deterioration; however, they crossed the
95th percentile at 26 days, 12 days, and 5 days before
delivery, respectively. At the last examination before delivery,
the proportion of increased MPI (70.4%) was significantly
higher than that of abnormal AoI PI (55.7%) and DV PI
(47.8%) [121]. Further research is needed to assess the
potential of MPI.
4.7. Histopathological and Molecular Diagnostics. Technological advances in the use of molecular probes have
enabled us to evaluate disease mechanisms and develop
laboratory-based assessment of placental injury. Genomic,
proteomics, and metabolomic tools may refine disease
diagnosis and provide therapeutic targets in FGR pregnancies. Acquisition of fetoplacental tissues or cells will be
necessary. Currently, sampling of amniotic fluid, fetal blood,
maternal blood, and tfetoplacental or transabdominally
obtained placental tissues is possible. The patterns of gene
expression that define hypoxic injury to trophoblasts are
not well understood. However, studies using techniques
such as high-density oligonucleotide microarrays, in situ
hybridization, and quantitative PCR are reporting that
placental villi from human pregnancies complicated by FGR
demonstrate characteristic changes in “hypoxic trophoblast
signature transcripts” [122]. For example, upregulation of
transcripts for vascular endothelial growth factor, connective tissue growth factor, follistatin-related protein, N-Myc
downstream-regulated gene1, and adipophilin (ADRP), and
downregulation of human placental lactogen and PHLDA2
[122] have been shown. For instance, dysregulation of
transcripts like CRH, IGF1, IGF2, AGTR1, leptin, and
sFlt have also been described. Imprinted genes such as
the maternally expressed/paternally repressed Phlda2 or the
paternally expressed/maternally repressed gene Mest are
diﬀerentially expressed in placentas from FGR fetuses [123].
These genes regulate fetal and placental growth, with paternally expressed genes encouraging growth and maternally
expressed genes reducing growth [124]. Protein families
such as cytokines, growth factors, and angiogenic peptides
are suggested to play a role in the pathogenesis of FGR
[125]. Proteomic techniques may provide an adjunct to the
genomic approaches. These techniques are novel; however,
the potential combination of fetal biophysical testing and
informatics-based molecular analysis may prove useful in the
future management of FGR.

5. Clinical Management of FGR
5.1. Therapeutic Interventions to Abolish or Attenuate the
Impact of FGR. The initial management of FGR entails
eliminating proven causes of impaired growth and encouraging a healthy intrauterine environment. Measures such as
improved nutrition, smoking cessation, avoidance of drugs,
and control of maternal disorders including hypertension
and renal dysfunction are important. When present, infectious diseases should be treated. Sonography is vital to
identify fetal malformations particularly if lethal and oﬀer
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fetal karyotyping. Previous studies including meta-analysis
evaluating interventions such as plasma volume expansion, oxygen supplementation, administration of glucose
or amino acids, and administration of low-dose aspirin to
the mother did not show a significant impact on perinatal
outcomes [126–128]. Smoking cessation and antimalarial
therapy appeared to prevent FGR, but were ineﬀective
in established FGR. Notably, a recent Cochrane review
suggests that nutritional advice to women and balanced
energy/protein supplements may be beneficial in ameliorating the risk of the disease [129, 130].
5.2. Surveillance of the Growth-Restricted Fetus. In the past,
studies evaluating benefits of antepartum surveillance methods in FGR pregnancies have been limited by wide inclusion criteria of high-risk conditions (FGR, pre-eclampsia,
diabetes) and diverse methodology. A recent review of four
studies involving 1,588 high or intermediate risk pregnancies
reported that antenatal fetal heart rate monitoring NST did
not appear to have a significant eﬀect on perinatal mortality
or morbidity [131]. Similarly, a Cochrane review on the role
of BPP in the management of high-risk pregnancies found no
diﬀerence between biophysical profile and alternative forms
of fetal assessment [101]. In contrast, Manning et al. suggest
that NST or BPP may define high-risk pregnancies where the
risk of in utero demise is high, and therefore early delivery
might be warranted [96]. Recent evidence suggests that UA
Doppler may reduce the need for antepartum interventions
and lower perinatal morbidity and mortality [106]. Doppler
interrogations of MCA, ductus venosus, or other venous
vessels are increasingly being used in obstetric practice.
5.3. Timing the Delivery of the Growth-Restricted Fetus.
Currently there is no single test that dictates the optimal
timing of delivery. Once FGR is established, signs of fetal
deterioration in biophysical and sonographic indices direct
a timed delivery. When FGR is diagnosed at full term (≥37
weeks by reliable dates), delivery is favored. A recent study
reported that in late-onset SGA fetuses with normal Doppler
velocimetry at diagnosis, there is progression from 37 weeks’
gestation with worsening cerebroplacental ratio, followed by
a decrease in MCA-PI [132]. There is evidence that term
singletons with SGA birth weights have a five to seven-fold
risk of developing cerebral palsy compared with gestational
age-matched infants with birthweights within normal limits.
Hence, there appears to be no advantage in delaying delivery
once term is reached [133].
At 34–37 weeks, the incidence of significant neonatal
morbidity is low and the risk of hyaline membrane disease
can be assessed by amniocentesis, hence, delivery is a less
complex issue [134]. When FGR occurs before 34 weeks
gestation, decision to deliver is more diﬃcult and is individualized. The recently concluded European Growth Restriction
Intervention Trial (GRIT) [135] compared the eﬀect of
preterm delivery (at 24–36 weeks), based on UA Doppler
waveform, with that of delayed delivery by other clinical
indicators. Women were randomly assigned to immediate
delivery for abnormal UA Doppler or a delayed delivery
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FGR suspected∗

Normal

Routine care

Follow-up growth
• Abnormal AFI
management
• NST∗∗
• Consider workup
for nonplacental
etiology of FGR

Initial assessment
• EFW
• AC
• AFI
Abnormal

Normal

UA Doppler
Abnormal

Elevated S/D
PI or RI

• BPP weekly∗∗∗
• UA Doppler weekly
• Growth every 2

A/REDF

Abnormal

weeks∗

• Inpatient management
• NST/BPP daily∗∗∗
• Doppler 2 times/week

(UA, MCA, venous)∗

Consider delivery,
particularly if abnormal
biophysical parameters
or venous Doppler

∗ Consider

delivery if at term or near term, or based on fetal lung maturity testing

∗∗ Workup

for potential etiology of FGR should be initiated. The management should be modified if fetal anomalies are found

∗∗∗ Recommended

fetal movement count as an adjunct to antepartum testing. More intense monitoring may be needed if

oligohydramnios is present

Figure 2: A proposed monitoring scheme in pregnancies complicated by FGR. This figure focuses on FGR associated with placental
dysfunction. See text for additional details.

based on the managing physicians belief that delivery
was warranted, subject to worsening tests or a favorable
gestational age. The main outcome variables were survival to
hospital discharge and developmental quotient at two years
of age. Of 548 pregnancies randomized into the study, there
was no diﬀerence in overall mortality between the immediate
delivery and the delayed delivery groups [135]. In the 2year follow-up study, there were no significant diﬀerences
between the groups in death or disability rates [136].
Interestingly, the fact that the managing physicians were
prepared to time the delivery even as early as 29–34 weeks
using a randomization process points to the uncertainty
regarding risk/benefit of immediate delivery. Unfortunately,
the GRIT study failed to address specific triggers for timing
of delivery. Therefore, the question as to the best indicator
for delivery remains unanswered by that study.
The longitudinal studies characterizing the sequence
of changes in fetal Doppler’s have shown that DV flow
waveforms become abnormal only in advanced stages of fetal
compromise [118]. Furthermore, DV abnormality precedes
the loss of short-term variability in the fetal heart rate, and in
90% of cases it becomes abnormal only 48–72 hours before

the biophysical profile [102, 117]. Hence, integration of both
DV Doppler and biophysical profile in the management of
preterm IUGR seems logical. Baschat et al. provided neonatal
outcomes specific for early-onset placenta-based fetal growth
restriction quantifying the impact of gestational age, birth
weight, and fetal cardiovascular parameters. From 24 to 32
weeks, major morbidity declined (56.6% to 10.5%). FGR
neonates delivered after 26 weeks had at least 50% chance
of survival. FGR neonates delivered before 26 weeks had
less than 50% chance of survival. Birthweight of 600 g, DV
Doppler and cord artery pH predicted neonatal mortality
and DV Doppler alone predicted intact survival [137].
There is an ongoing randomised multicentre study of
timing delivery in women found to have FGR on ultrasound
scan at gestations between 26 and 32 weeks (trial of
umbilical and fetal flow in Europe, TRUFFLE). It is aimed
at evaluating the role of DV assessment (early DV changes
(pulsatility index >95th centile) and late DV changes (awave reaches the baseline, i.e., 0 cm/s) compared to standard
management based on fetal heart rate monitoring (shortterm variation below preset cut-oﬀs based on gestation)
for timely delivering early-onset IUGR cases. The primary
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outcome for this trial is survival without neurodevelopmental impairment at 2 years of age corrected for prematurity.
http://www.truﬄestudy.org/.
Diﬀerent obstetric centers currently depend on either
biophysical tests (NST, computerized NST, BPP, and alike)
or Doppler blood flow studies in order to time delivery.
Using published data, we developed a decision tree to explore
the optimal antepartum test for timing the delivery of the
preterm FGR fetus [138]. This is specific to our unit. Our
retrospective decision analysis indicated that BPP was the
best test to guide decisions on delivery of the preterm
growth-restricted fetus. Clearly, our results must be corroborated by a well-designed, prospective clinical trial prior to
universal acceptance. Figure 2 presents a proposed pathway
for the antenatal monitoring of the growth-restricted fetus.
The decision to deliver a growth-restricted fetus must be
individualized and balanced with available local perinatalneonatal services. What is clear is that after 34 completed
weeks, the appearance of advanced, worsening signs of fetal
deterioration, such as UA absent or reversed diastolic flow,
persistent nonreassuring NST, a BPP score of ≤4, reversed “a”
wave of the DV, or umbilical vein pulsations suggest the need
for immediate delivery [139]. Furthermore, the decision to
administration of a course of steroids, which reduce the
incidence of hyaline membrane disease in every preterm,
growth-restricted fetus, is unequivocal.
5.4. The Mode of Delivery of the Growth-Restricted Fetus.
There is contradictory evidence in the literature regarding
the best mode of delivery of the growth-restricted fetus.
A vaginal delivery is rarely attempted when biophysical
assessment of fetal status is nonreassuring prior to labor
because fetal hypoxia may be exacerbated. Even when
biophysical parameters are reassuring, clinicians vary in their
decisions. In the GRIT study, one third of the pregnancies
with FGR were delivered by the abdominal route, yet it
is not clear if there was any benefit from this approach
[135]. A recent Cochrane review pointed out that Caesarean
delivery for SGA fetuses was associated with a lower rate
of respiratory distress syndrome, neonatal seizures, and
death, but these trends were statistically insignificant [140].
Obviously, other obstetrical factors such as the gestational
age, cervical status, fetal presentation, and maternal medical
complications may influence the choice of delivery route.
Because the growth restricted fetus may require specialized
neonatal care, particularly when the delivery occurs preterm,
it is prudent to transfer the fetus to a well-equipped center
where experienced perinatal-neonatal care is available.

6. Conclusion
Significant advances have been made in the understanding
of the complex etiology and pathophysiology of FGR.
This knowledge will certainly aid the clinician to optimize
antepartum monitoring and time delivery of FGR infants.
Biophysical tests and multivessel Doppler have predictive
abilities in detecting academia but their strengths need
further evaluation. The temporal correlation between the
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commonly used tools and preterminal fetal status remains
unclear. There are emerging recommendations to combine
the use of multiple monitoring tools in models to improve
the prediction of adverse outcome. Nonetheless, there is
still no definitive cure for FGR and management strategies
for pregnancies complicated by FGR, are based on limited
evidence. Well-designed randomized clinical trials are much
needed that specifically target the diﬀerent management
options.
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